Clinical Trial Update: A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating subcutaneous administration of trastuzumab (Herceptin) at home for HER2-positive early breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED